SCHEDULE 13G/A: Morgan Stanley Discloses 5.0% Passive Stake in Theratechnologies Inc.

Morgan Stanley has filed an amended Schedule 13G, revealing a 5.0% beneficial ownership stake in Theratechnologies Inc. as of December 31, 2024.

Summary

• Morgan Stanley, a Delaware-based parent holding company, reported beneficial ownership of 2,313,769 common shares of Theratechnologies Inc.
• This ownership represents 5.0% of the total class of securities.
• Morgan Stanley holds shared voting power over 2,274,552 shares and shared dispositive power over 2,313,769 shares.
• The filing is an Amendment No. 2 to Schedule 13G, indicating a passive investment.
• The CUSIP number for Theratechnologies Inc. common shares was updated to 88338H704* to reflect a 4-for-1 reverse stock split effective July 31, 2023.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in tone. The presence of a major institutional investor can be seen as a positive signal, but the filing itself does not contain operational or financial performance data to assess sentiment beyond the ownership stake.

Positives

• The disclosure of a 5.0% stake by a major institutional investor like Morgan Stanley can be perceived as a vote of confidence in Theratechnologies Inc. by the market.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, indicating a passive and potentially stable investment.

Risks

• The document itself does not detail specific operational or financial risks of Theratechnologies Inc., focusing solely on beneficial ownership disclosure.
• The certification by Morgan Stanley mitigates the risk of an activist investor seeking to influence or change control of the issuer.

Future Outlook

This document is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance from Theratechnologies Inc. or Morgan Stanley regarding the issuer's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Morgan Stanley)

Industry Context

This filing represents a standard institutional ownership disclosure, indicating that a major financial institution, Morgan Stanley, holds a significant passive stake in Theratechnologies Inc., a company operating in the biotechnology or pharmaceutical sector. Such disclosures are common and reflect portfolio management activities by large investment firms.

Comparison to Industry Standards

• Not applicable as this document is a beneficial ownership disclosure, not a financial or operational performance report. Therefore, it does not provide comparable company results, projects, or specific financial benchmarks.

Stakeholder Impact

• Shareholders: The disclosure of a 5.0% stake by Morgan Stanley may instill confidence among existing shareholders and potentially attract new investors, as it signals significant institutional interest in the company.

Key Dates

Keywords

Theratechnologies, Morgan Stanley, Schedule 13G, Beneficial Ownership, Institutional Ownership, Common Shares, SEC Filing, Passive Investment, Reverse Stock Split